Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19.

Autor: Franco V; Division of Cardiovascular Disease, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Bradley EA; Division of Cardiovascular Disease, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Badagliacca R; Department of Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy., Sabanayagam A; Division of Cardiovascular Disease, University of California San Francisco, USA., Rajpal S; Division of Cardiovascular Disease, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Lastinger LT; Division of Cardiovascular Disease, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Daniels CJ; Division of Cardiovascular Disease, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Smith JS; Division of Pulmonary, Critical Care and Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Benza RL; Division of Cardiovascular Disease, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Jazyk: angličtina
Zdroj: Pulmonary circulation [Pulm Circ] 2020 Nov 20; Vol. 10 (4), pp. 2045894020970369. Date of Electronic Publication: 2020 Nov 20 (Print Publication: 2020).
DOI: 10.1177/2045894020970369
Abstrakt: Pulmonary arterial hypertension (PAH) and novel coronavirus (SARS-CoV-2) disease COVID-19 are characterized by extensive endothelial dysfunction and inflammation leading to vascular remodeling and severe microthrombi and microvascular obliterative disease. It is hypothesized that those patients with underlying lung disease, like PAH, represent a high-risk cohort in this pandemic. However, reports of COVID-19 in this cohort of patient have been scaring and an observational survey showed that the disease was relatively well tolerated. We postulate that specific PAH vasodilator may offer some protection and/or advantage in the case of concomitant COVID-19. Here we review the literature describing mechanisms of action for each of the broad categories of PAH therapy, and offer potential hypothesis about why this therapy may impact outcomes in COVID-19.
Competing Interests: Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: VF, RJ, CJD, JSS -- research support UT, Bayer, Actelion, PhaseBio, Liquidia RB -- speaker / advisory boards from Bayer, MSD, Dompe, Galenica, GSK, Actelion, Ferrer, AOP, UT RLB -- research support UT, PhaseBio, Liquidia, Cerano, Abbott.
(© The Author(s) 2020.)
Databáze: MEDLINE
Externí odkaz: